These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 8483888)
21. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414 [TBL] [Abstract][Full Text] [Related]
22. [Cell-block immunocytochemical characterization of effusions. Use of antibody panel: calretinin, Ber-EP4, keratin and CD68]. Lucchi I; Morigi F; Naldi S; Tabarri B; Elegibili E; Giangaspero F Pathologica; 1999 Dec; 91(6):447-52. PubMed ID: 10783640 [TBL] [Abstract][Full Text] [Related]
23. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. Ko EC; Jhala NC; Shultz JJ; Chhieng DC Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688 [TBL] [Abstract][Full Text] [Related]
24. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review]. Galateau-Salle F Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582 [TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Wirth PR; Legier J; Wright GL Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354 [TBL] [Abstract][Full Text] [Related]
26. Uterine adenomatoid tumors: immunohistochemical characteristics with emphasis on Ber-EP4 immunoreactivity and distinction from adenocarcinoma. Otis CN Int J Gynecol Pathol; 1996 Apr; 15(2):146-51. PubMed ID: 8786204 [TBL] [Abstract][Full Text] [Related]
27. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688 [TBL] [Abstract][Full Text] [Related]
28. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Afify AM; Stern R; Michael CW Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337 [TBL] [Abstract][Full Text] [Related]
29. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation. Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489 [TBL] [Abstract][Full Text] [Related]
30. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. Sheibani K; Battifora H; Burke JS Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942 [TBL] [Abstract][Full Text] [Related]
31. Distinction between cells in serous effusions using a panel of antibodies. Lauritzen AF Virchows Arch A Pathol Anat Histopathol; 1987; 411(3):299-304. PubMed ID: 2441518 [TBL] [Abstract][Full Text] [Related]
32. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Bedrossian CW; Bonsib S; Moran C Semin Diagn Pathol; 1992 May; 9(2):124-40. PubMed ID: 1609155 [TBL] [Abstract][Full Text] [Related]
33. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Ruitenbeek T; Gouw AS; Poppema S Arch Pathol Lab Med; 1994 Mar; 118(3):265-9. PubMed ID: 8135629 [TBL] [Abstract][Full Text] [Related]
34. Immunocytochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies. Zeng L; Fleury-Feith J; Monnet I; Boutin C; Bignon J; Jaurand MC Hum Pathol; 1994 Mar; 25(3):227-34. PubMed ID: 7512071 [TBL] [Abstract][Full Text] [Related]
35. Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Jordon D; Jagirdar J; Kaneko M Am J Pathol; 1989 Nov; 135(5):931-7. PubMed ID: 2817084 [TBL] [Abstract][Full Text] [Related]
36. Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung. Tron V; Wright JL; Churg A Arch Pathol Lab Med; 1987 Mar; 111(3):291-3. PubMed ID: 2435259 [TBL] [Abstract][Full Text] [Related]
37. [Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect]. Marsan C; Gaulier A; Sabatier P; Garcia R Arch Anat Cytol Pathol; 1993; 41(5-6):223-8. PubMed ID: 8135583 [TBL] [Abstract][Full Text] [Related]
38. Expression of epithelial membrane antigen on malignant mesothelioma cells. An immunocytochemical and immunoelectron microscopic study. van der Kwast TH; Versnel MA; Delahaye M; de Jong A; Zondervan PE; Hoogsteden H Acta Cytol; 1988; 32(2):169-74. PubMed ID: 3348058 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of membranous staining of mesothelioma. King JA; Tucker JA Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721 [TBL] [Abstract][Full Text] [Related]
40. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Sheibani K; Shin SS; Kezirian J; Weiss LM Am J Surg Pathol; 1991 Aug; 15(8):779-84. PubMed ID: 2069213 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]